|The full article is available to subscribers||Subscriber Login|
22. H Binsfeld et al. A randomized study to demonstrate noninferiority of once-daily OROS hydromorphone with twice-daily sustained-release oxycodone for moderate to severe chronic noncancer pain. Pain Pract 2010; 10:404.
25. FDA. FDA reminds the public about the potential for life-threatening harm from accidental exposure to fentanyl transdermal systems ("patches"). April 18, 2012. Available at www.fda.gov/Drugs/DrugSafety/ucm300747.htm.
32. FDA. FDA Drug Safety Communication: safety review update of codeine use in children; new boxed warning and contraindication on use after tonsillectomy and /or adenoidectomy. February 20, 2013. Available at www.fda.gov/Drugs/DrugSafety/ucm339112.htm. Accessed March 7, 2013.
61. FDA. FDA drug safety communication: rare cases of serious burns with the use of over-the-counter topical muscle and joint pain relievers. Available at www.fda.gov/Drugs/DrugSafety/ucm318858.htm. Accessed March 8, 2013.